In transition-age childhood-onset growth hormone deficiency, growth hormone response to the glucagon stimulation test depends mainly on pituitary dysfunction severity, with BMI having minimal impact.

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving ...

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes, providing ...

SAN ANTONIO, Nov. 25, 2025 – From metabolic villain to hero? The hormone glucagon that raises blood sugar is now getting a second look to see how it actually contributes to insulin secretion, glucose ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

New fleet of weight loss drugs are more effective than the current popular obesity medications at trial - One in eight ...

Nanosized particles that release glucagon, the hormone responsible for raising blood glucose levels, on-demand could mean that diabetics don’t need to worry about potentially dangerous low blood sugar ...

People with diabetes take insulin to lower high blood sugar. However, if glucose levels plunge too low—from taking too much insulin or not eating enough sugar—people can experience hypoglycemia, which ...